LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Search

Ascendis Pharma A-S ADR

Cerrado

SectorSalud

218.15 4.49

Resumen

Variación precio

24h

Actual

Mínimo

207.85

Máximo

228

Métricas clave

By Trading Economics

Ingresos

-22M

-61M

Ventas

56M

214M

Margen de beneficio

-28.549

Empleados

1,017

EBITDA

-56M

-53M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+18.24% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

785M

13B

Apertura anterior

213.66

Cierre anterior

218.15

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

153 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Ascendis Pharma A-S ADR Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

13 dic 2025, 00:04 UTC

Adquisiciones, fusiones, absorciones

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

12 dic 2025, 16:42 UTC

Adquisiciones, fusiones, absorciones

FTC Sues to Block Henkel's $725 Million Deal for Liquid Nails From PE Firm -- 2nd Update

13 dic 2025, 16:48 UTC

Adquisiciones, fusiones, absorciones

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13 dic 2025, 08:00 UTC

Adquisiciones, fusiones, absorciones

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13 dic 2025, 07:00 UTC

Adquisiciones, fusiones, absorciones

A Chubb/AIG Deal Could Be Good for Shareholders and a Coup for Greenberg Family -- Barrons.com

13 dic 2025, 00:24 UTC

Adquisiciones, fusiones, absorciones

Want a Piece Of SpaceX? -- Barrons.com

12 dic 2025, 23:49 UTC

Adquisiciones, fusiones, absorciones

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12 dic 2025, 22:52 UTC

Charlas de Mercado

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12 dic 2025, 22:32 UTC

Ganancias

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12 dic 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

12 dic 2025, 20:45 UTC

Ganancias

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12 dic 2025, 20:41 UTC

Charlas de Mercado

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12 dic 2025, 20:20 UTC

Charlas de Mercado

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12 dic 2025, 19:23 UTC

Ganancias

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12 dic 2025, 18:35 UTC

Adquisiciones, fusiones, absorciones

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12 dic 2025, 18:33 UTC

Adquisiciones, fusiones, absorciones

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12 dic 2025, 18:31 UTC

Charlas de Mercado

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12 dic 2025, 17:49 UTC

Ganancias

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12 dic 2025, 17:34 UTC

Adquisiciones, fusiones, absorciones

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

12 dic 2025, 17:33 UTC

Adquisiciones, fusiones, absorciones

Orange: Closing of the Transaction Is Expected in the First Half of 2026

12 dic 2025, 17:33 UTC

Adquisiciones, fusiones, absorciones

Orange: Agreement Confirms the Non-Binding Agreement That Was Previously Announced Oct. 31

12 dic 2025, 17:32 UTC

Adquisiciones, fusiones, absorciones

Orange: MasOrange Is Spain's Leading Operator in Terms of Customer Base

12 dic 2025, 17:31 UTC

Adquisiciones, fusiones, absorciones

Orange to Buy the Stake for EU4.25B in Cash

12 dic 2025, 17:24 UTC

Charlas de Mercado

Argentina Predicts Record Wheat Crop -- Market Talk

12 dic 2025, 17:20 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

12 dic 2025, 17:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

12 dic 2025, 17:18 UTC

Charlas de Mercado
Ganancias

Broadcom, Oracle Investor Reactions Show High Bar for AI Cos. -- Market Talk

12 dic 2025, 17:09 UTC

Charlas de Mercado

Broadcom Investors Were Primed to Sell Shares -- Market Talk

12 dic 2025, 17:09 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

12 dic 2025, 16:47 UTC

Charlas de Mercado

Broadcom's Margins Expected to Narrow Due to AI Revenue -- Market Talk

Comparación entre iguales

Cambio de precio

Ascendis Pharma A-S ADR Esperado

Precio Objetivo

By TipRanks

18.24% repunte

Estimación a 12 meses

Media 260.62 USD  18.24%

Máximo 325 USD

Mínimo 220 USD

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ascendis Pharma A-S ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

14 ratings

14

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

157.66 / 167.29Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Strong Bullish Evidence

Sentimiento

By Acuity

153 / 374 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
help-icon Live chat